Genome editing via non-viral delivery platforms: current progress in personalized cancer therapy

Table 1 Registered clinical trials using non-viral systems to deliver genome editing-based anticancer therapies

Delivery system	GET	Edited cell	Target Gene	Phase	NCT Number
Lipid Nanoparticles	CRISPR-Cas9	T cells	TCR	I/II	NCT05066165
Electroporation	CRISPR-Cas9	T cells	TCR, HLA-class I and HLA-class II	I	NCT05037669
Electroporation	CRISPR-Cas9	T cells	CD5	I	NCT04767308
Electroporation	CRISPR-Cas9	T cells	HPK1	I	NCT04037566
Electroporation	CRISPR-Cas9	T cells	TCR and PD-1	I	NCT03399448
Electroporation	CRISPR-Cas9	T cells	TCR and B2M	I/II	NCT03166878
Electroporation	CRISPR-Cas9	T cells	PD-1	I	NCT02793856
Plasmid in gel	CRISPR-Cas9 TALEN	Cancer cells	HPV E6/E7	I	NCT03057912

ISSN: 1476-4598